NCT00767247

Brief Summary

Analysis of antihypertensive treatment efficacy.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2008

Shorter than P25 for all trials

Geographic Reach
1 country

13 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2008

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 6, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 7, 2008

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2009

Completed
Last Updated

December 3, 2010

Status Verified

December 1, 2010

Enrollment Period

9 months

First QC Date

October 6, 2008

Last Update Submit

December 2, 2010

Conditions

Arterial Hypertension

Keywords

Arterial Hypertension

Outcome Measures

Primary Outcomes (1)

  • Analysis of antihypertensive treatment efficacy.

    measurement BP: 3 visits for 3 month

Study Arms (1)

1

Male or female with arterial hypertension

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

outpatient clinics

You may qualify if:

  • arterial hypertension
  • intake of Atacand before study enrollment

You may not qualify if:

  • hypersensitivity to candesartan or any other ingredient of Atacand
  • liver function impairment and/or cholestasis
  • severe renal insufficiency (serum creatinine \> 265 µmol/L)
  • Pregnant and lactating women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Research Site

Arhangelsk, Russia

Location

Research Site

Bryansk, Russia

Location

Research Site

Domodedovo, Russia

Location

Research Site

Dzerzhinsk, Russia

Location

Research Site

Georgiyevsk, Russia

Location

Research Site

Irkutsk, Russia

Location

Research Site

Kazan', Russia

Location

Research Site

Samara, Russia

Location

Research Site

Severodvinsk, Russia

Location

Research Site

Vidnoye, Russia

Location

Research Site

Volgograd, Russia

Location

Research Site

Yekaterinburg, Russia

Location

Research Site

Yessentuki, Russia

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Dmitry Zateyshchikov, MD, Prof

    Federal State Institution of Russian President's General Management Department

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

October 6, 2008

First Posted

October 7, 2008

Study Start

May 1, 2008

Primary Completion

February 1, 2009

Study Completion

February 1, 2009

Last Updated

December 3, 2010

Record last verified: 2010-12

Locations

RU(13)